This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-39. (Canceled)

40. (Previously presented) A method for the management of incontinence in a patient, wherein the method comprises admitting orally into the patient a dosage form comprising 5 mg to 250 mg of a member selected from the set consisting of oxybutynin and its pharmaceutically acceptable salt, wherein said dosage form delivers said member from said dosage form to the patient at a substantially zero order rate of release over the period of about 24 hours.

41. (Previously presented) The method according to Claim 40, wherein said salt is oxybutynin hydrochloride.

42. (Previously presented) The method according to Claim 40, wherein said dosage form further comprises a member selected from the group consisting of hydroxypropylmethylcellulose, hydroxypropylethylcellulose, hydroxypropylbutylcellulose, and hydroxypropylpentylcellulose.

43. (Previously presented) The method according to Claim 41, wherein said dosage form further comprises a member selected from the group consisting of hydroxypropylmethylcellulose, hydroxypropylethylcellulose, hydroxypropylbutylcellulose, and hydroxypropylpentylcellulose.

44. (Previously presented) The method according to Claim 40, wherein said dosage form is a tablet.

45. (Previously presented) The method according to Claim 41, wherein said dosage form is a tablet.

46. (Previously presented) The method according to Claim 42, wherein said dosage form is a tablet.

47. (Previously presented) The method according to Claim 43, wherein said dosage form is a tablet.

48. (Previously presented) The method according to any one of Claims 40, 41, 42, 43, 44, 45, 46 or 47 wherein the incidence of side effects associated with oxybutynin treatment is reduced.